94581
Hirudin recombinant from yeast
lyophilized powder, white, >1500 U/vial
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
synthetic
yeast (Pichia pastoris)
form
lyophilized powder
specific activity
>1500 U/vial
mol wt
Mr ~6963.5
color
white
solubility
0.1 M Tris, 0.2 M NaCl, pH 8.4: 1 vial/mL, clear, colorless
storage temp.
−20°C
Application
Recombinant hirudin from yeast has been used in mannan-binding lectin serine protease 2 (MASP2) activation assay. It has also been used in pre-treating the nanosheets in phosphate buffered saline (PBS) for platelet adhesion assay.
Biochem/physiol Actions
Recombinant hirudin appears to be antigenic. Independent studies have found that 50-70% of patients treated for several days with recombinant hirudin develop at least one hirudin antibody isotype. The antibodies reduce the anticoagulant effect of hirudin, but prolong its plasma half-life by reducing renal filtration.
The anticoagulant, hirudin, is the most potent natural inhibitor of both soluble and clot-bound thrombin. It binds thrombin with high affinity, covering more than 20% of its surface area and occluding both the active site and exosite I (fibrinogen and PAR recognition site). Hirudin blocks thrombus growth and platelet activation. It is not metabolized in the bloodstream of humans and is eliminated unchanged via kidney filtration.
Unit Definition
1 U corresponds to 1 ATU (antithrombin unit; 1 ATU is defined as the amount of inhibitor that neutralizes 1 NIH unit of thrombin).
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Volker Liebe et al.
Seminars in thrombosis and hemostasis, 28(5), 483-490 (2002-11-07)
This article provides an overview of the clinically relevant characteristics of antibodies directed toward recombinant (r) hirudin, with emphasis on the different ways in which these antibodies may influence pharmacokinetics and pharmacodynamics of r-hirudin. A high incidence of anti-hirudin antibody
Multiple routes of complement activation by Mycobacterium bovis BCG
Carroll MV, et al.
Molecular Immunology, 46(16), 3367-3378 (2009)
A few immobilized thrombins are sufficient for platelet spreading
Okamura Y, et al.
Biophysical Journal, 100(8), 1855-1863 (2011)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service